Jennifer Taubert

In a year of shakeup in the J&J C-suite—Joaquin Duato will take over from longtime chief Alex Gorsky in January—Taubert has been a beacon of stability (and a focus of speculation about future CEO contenders). As head of J&J’s pharma unit, she oversaw more than half of the company’s $82.6 billion in 2020 revenue. She’s also been leading the charge on J&J’s COVID vaccine, which, though it stumbled early on over safety concerns, is now expected to bring in approximately $2.5 billion in 2021 revenue. Taubert’s division has also been buoyed by efforts to grow the company’s footprint in non-COVID treatment spaces.

Subscribe to The Broadsheet, our newsletter on the world’s most powerful women.